Andreana N. Holowatyj, PhD, MS, Discusses Focal Questions Regarding Colorectal Cancer Disparities

Video

Holowatyj touched on the need to learn more about the biological factors contributing to disparities in early-onset colorectal cancer and the associated burden of the disease.

Andreana N. Holowatyj, PhD, MS, of the Vanderbilt University Medical Center, spoke with CancerNetwork about the focal questions from her research presented at the American Association for Cancer Research (AACR) Annual Meeting 2021 focusing on disparities in early-onset colorectal cancer.

Transcription:

We sought to tackle the loaded question to understand what biological factors may be contributing to disparities in the early-onset colorectal cancer burden. To put things into perspective, overall about 1 in every 10 colorectal cancer cases is diagnosed prior to age 50. There’s been a challenge to date in accruing sufficient cases or data to be able to explore this timely and important research question as to differences within the population of early-onset colorectal cancer, particularly the molecular features. It was a really unique opportunity to leverage the resource of the AACR Project GENIE [Genomic Evidence Neoplasia Information Exchange] consortium that included both clinical-grade targeted sequencing data, and clinical demographic data on cases with a pathologically confirmed colorectal cancer diagnosis from 12 institutions worldwide, which was [a] prime opportunity to answer this research question with over 6000 colorectal cancer cases included in our study.

Reference:

Holowatyj AN, Wen W, Gibbs T, et al. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases. Presented at: AACR Annual Meeting 2021. Virtual. Abstract 101.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Related Content